Zacks Investment Research cut shares of ProQR Therapeutics N.V. (NASDAQ:PRQR) from a buy rating to a hold rating in a research report sent to investors on Friday, October 6th.
According to Zacks, “ProQR Therapeutics B.V. is a biotech company. It is engaged in the discovery and development of RNA-based therapeutics for the treatment of severe genetic disorders, with an initial focus on Cystic Fibrosis (CF). The Company’s lead product candidate includes QR-010, a RNA-based oligonucleotide for the treatment of cystic fibrosis. ProQR Therapeutics B.V. is headquartered in Leiden, the Netherlands. “
Several other brokerages also recently weighed in on PRQR. Leerink Swann reiterated an outperform rating and issued a $12.00 price target (up from $10.00) on shares of ProQR Therapeutics N.V. in a report on Tuesday, September 26th. JMP Securities boosted their price target on ProQR Therapeutics N.V. from $14.00 to $20.00 and gave the company an outperform rating in a report on Tuesday, September 26th. ValuEngine upgraded ProQR Therapeutics N.V. from a strong sell rating to a sell rating in a report on Friday, September 1st. Chardan Capital reiterated a neutral rating on shares of ProQR Therapeutics N.V. in a report on Sunday, September 17th. Finally, HC Wainwright reissued a buy rating and set a $40.00 price objective on shares of ProQR Therapeutics N.V. in a research note on Tuesday, September 26th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and three have issued a buy rating to the company. ProQR Therapeutics N.V. has a consensus rating of Hold and a consensus price target of $16.40.
ProQR Therapeutics N.V. (NASDAQ:PRQR) opened at 4.45 on Friday. The stock’s market cap is $107.27 million. The company’s 50-day moving average price is $5.14 and its 200-day moving average price is $5.03. ProQR Therapeutics N.V. has a 12-month low of $3.65 and a 12-month high of $8.70.
COPYRIGHT VIOLATION NOTICE: This news story was originally published by BBNS and is owned by of BBNS. If you are accessing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The correct version of this news story can be accessed at https://baseballnewssource.com/markets/zacks-investment-research-downgrades-proqr-therapeutics-n-v-prqr-to-hold/1703144.html.
Large investors have recently bought and sold shares of the business. Janus Henderson Group PLC purchased a new position in ProQR Therapeutics N.V. in the 2nd quarter valued at about $2,028,000. Artal Group S.A. boosted its position in ProQR Therapeutics N.V. by 25.0% in the 2nd quarter. Artal Group S.A. now owns 500,000 shares of the biopharmaceutical company’s stock valued at $2,600,000 after buying an additional 100,000 shares during the last quarter. Finally, Redmile Group LLC boosted its position in ProQR Therapeutics N.V. by 2.8% in the 2nd quarter. Redmile Group LLC now owns 1,596,275 shares of the biopharmaceutical company’s stock valued at $8,301,000 after buying an additional 43,050 shares during the last quarter. 35.93% of the stock is owned by institutional investors.
About ProQR Therapeutics N.V.
ProQR Therapeutics N.V. (ProQR), formerly ProQR Therapeutics B.V., is a pre-clinical stage biopharmaceutical company. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. Utilizing its RNA repair technologies, the Company is developing a pipeline in severe genetic disorders, such as cystic fibrosis (CF) and Leber’s congenital amaurosis (LCA).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ProQR Therapeutics N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics N.V. and related companies with our FREE daily email newsletter.